|
Hepatitis C
|
0.200 |
Biomarker
|
disease |
BEFREE |
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C.
|
23358218 |
2013 |
|
Hepatitis C
|
0.200 |
Biomarker
|
disease |
BEFREE |
Together, these findings result in the paradox that IFNλ4 is strongly antiviral but a disadvantage during HCV infection.
|
24169568 |
2013 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
|
23939236 |
2013 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Upstream of IFNL3 (IL28B) on chromosome 19q13.13, we discovered a new transiently induced region that harbors a dinucleotide variant ss469415590 (TT or ΔG), which is in high linkage disequilibrium with rs12979860, a genetic marker strongly associated with HCV clearance. ss469415590[ΔG] is a frameshift variant that creates a novel gene, designated IFNL4, encoding the interferon-λ4 protein (IFNL4), which is moderately similar to IFNL3.
|
23291588 |
2013 |
|
Hepatitis C
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Their amounts were positively related to liver HCV RNA copy numbers (p = 0.0023, r = 0.56) suggesting that the hepatic viral load influences IFNL4 transcription irrespective of IFNL4 governing genotype.
|
24376784 |
2013 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that a common amino acid substitution in HLA-DQB1 affects susceptibility to chronic infection with HCV in the Japanese population and may not be independent of the IFNL4 genotype.
|
24376798 |
2013 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
TVR given at 12 h intervals should be considered for patients with lower body weight, especially patients with prior relapse and with IL28B polymorphisms at rs8099917 TT (interferon-λ 4 ss469415590 polymorphism TT/TT) genotype in patients with genotype 1b HCV infection.
|
24192751 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 and IL28B polymorphisms were genotyped in 86 HCV-infected LT recipients and in their donors; all patients had undergone antiviral treatment with pegylated interferon and ribavirin after LT.
|
25130512 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
|
24072198 |
2014 |
|
Hepatitis C
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Resolving the paradoxical functions of IFN-λ4, which appears to induce antiviral activity yet impair effective clearance of HCV, may yield critical new insights into the immunologic response to HCV infection and IFN biology.
|
24786669 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.
|
24646752 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.
|
23956438 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
|
24367041 |
2014 |
|
Hepatitis C
|
0.200 |
Biomarker
|
disease |
BEFREE |
The underlying biological mechanism that links the above IL-28B polymorphisms (in both IFN-λ3 and IFN-λ4) to spontaneous and treatment-induced clearance of HCV infection remains to be discovered.
|
25273834 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have shown an association between single nucleotide polymorphisms (SNPs) in the interferon lambda-3 (IFNL3 or IL-28B) and IFNL4 genes and treatment response to hepatitis C virus genotype 1 (HCV-1) infection.
|
24782280 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 polymorphisms and HCV genotypes were determined.
|
24415789 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 ss469415590 (ΔG) allele carriers have an impaired clearance of HCV infection and response to IFN-α therapy.
|
24205831 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Interferon-λ4-related dinucleotide variant rs368234815 TT/-G is strongly linked with rs12979860 polymorphism, the most important genetic marker connected to treatment-induced hepatitis C virus clearance.
|
24724563 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.
|
24748394 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To assess whether a dinucleotide variant of IFNL4 (ss469415590) also affected treatment outcome of antiviral therapy in Japan, we genotyped 213 patients with chronic genotype 1 HCV infection and 176 healthy subjects.
|
24355007 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IFNL4 ss469415590 polymorphism has been reported as a novel predictor of the response to IFN therapy for chronic HCV infection.
|
24750545 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We assessed predictive factors for sustained virological response (SVR) to triple therapy in 226 younger (≤65 years) and 87 older (>65 years) Japanese patients with chronic genotype 1 hepatitis C. IFNL4 polymorphism ss469415590 was analyzed by Invader assay.
|
24362944 |
2014 |
|
Hepatitis C
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Altogether, these data provide evidence supporting a role for the active IFNλ4 protein as the driver of high hepatic ISG expression as well as the cause of poor HCV clearance.
|
25534433 |
2014 |
|
Hepatitis C
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, it was shown that the polymorphism of IFN-lambda 4 (IFNL4) is in high linkage disequilibrium with that of near IL28B, and more strongly associated with spontaneous or treatment-induced HCV clearance than IL28B genotypes, especially in individuals of African ancestry.
|
24325405 |
2014 |
|
Hepatitis C
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Functional IFN-λ4 has antiviral activity but the elimination of IFN-λ4 through pseudogenization is strongly associated with improved clearance of hepatitis C virus (HCV) infection.
|
25329461 |
2014 |